1. Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.
- Author
-
Pollan, Sara G, Teng, Pai-Chi, Jan, Yu Jen, Livingstone, Julie, Huang, Cai, Kim, Minhyung, Mariscal, Javier, Rodriguez, Maria, Chen, Jie-Fu, You, Sungyong, DiVizio, Dolores, Boutros, Paul C, Chan, Keith Syson, Rasorenova, Olga, Cress, Anne, Spassov, Danislav, Moasser, Mark, Posadas, Edwin M, Freedland, Stephen J, Freeman, Michael R, Zheng, Jie J, and Knudsen, Beatrice S
- Subjects
CDCP1 ,PIP5K1c ,anoikis ,focal adhesion kinase ,prostate cancer metastasis ,Urologic Diseases ,Cancer ,Prostate Cancer ,Aetiology ,2.1 Biological and endogenous factors - Abstract
A major metastasis suppressing mechanism is the rapid apoptotic death of cancer cells upon detachment from extracellular matrix, a process called anoikis. Focal adhesion kinase (PTK2/FAK) is a key enzyme involved in evasion of anoikis. We show that loss of the Cub-domain containing protein-1 (CDCP1), paradoxically stimulates FAK activation in the detached state of prostate cancer cells. In CDCP1low DU145 and PC3 prostate cancer cells, detachment-activation of FAK occurs through local production of PI(4,5)P2. PI(4,5)P2 is generated by the PIP5K1c-201 splicing isoform of PIP5K1c, which contains a unique SRC phosphorylation site. In the detached state, reduced expression of CDCP1 and an alternative CDCP1-independent SRC activation mechanism triggers PIP5K1c-pY644 phosphorylation by SRC. This causes a switch of Talin binding from β1-integrin to PIP5K1c-pY644 and leads to activation of PIP5K1c-FAK. Reduced CDCP1 expression also inactivates CDK5, a negative regulator of PIP5K1c. Furthermore, immersion of prostate cancer cells in 10% human plasma or fetal bovine serum is required for activation of PIP5K1c-FAK. The PIP5K1c induced detachment-activation of FAK in preclinical models sensitizes CDCP1low prostate cancer cells to FAK inhibitors. In patients, CDCP1High versus CDCP1low circulating tumor cells differ in expression of AR-v7, ONECUT2 and HOXB13 oncogenes and TMPRSS2 and display intra-patient heterogeneity of FAK-pY397 expression. Taken together, CDCP1low and CDCP1high detached prostate cancer cells activate distinct cytoplasmic kinase complexes and targetable transcription factors, which has important therapeutic implications.
- Published
- 2021